Despite these hurdles, both LMP1 and LMP2 have high expression in NPC and are relatively immunogenic [22, 23], rendering them suitable candidates for EBV-targeted immunotherapy. This evidence concerns the gene PDLIM7 and nasopharyngeal carcinoma.